How safe and effective is dapagliflozin for improving health markers in people with obesity

Study of efficacy and safety of dapagliflozin on metabolic parameters in patients of obesity. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098835

Enrollment

Registered

2025-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Dapagliflozin: give dapagliflozin 10 mg to patients after screening for next 6 month Intervention2: dapagliflozin: dapagliflozin 10 mg for 6 months Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: with BMI more than 25 Patient willing to participate in the study and give written informed consent

Exclusion criteria

Exclusion criteria: 1 Patients with type 1 diabetes or type 2 diabetes mellitus 2 Patients with thyroid dysfunction 3 Patients taking concurrent medications known to cause weight gain 4 Patients with a history of UTI or recurrent genitourinary infection 5 Patients with renal and hepatic impairment 6 Patients showing intolerance to dapagliflozin 7 Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
measure dapagliflozin effects on Hba1c FBS BMI at baseline and after 6 months in Indian obese patients.Timepoint: visit 0 at baseline and Visit 1 at 6 months then End of Study Investigation	—

Secondary

Measure	Time frame
To study the occurrence of adverse drug reaction of dapagliflozinTimepoint: 2 years	—

Countries

India

Contacts

Public Contactdr shruti chandra

MGM Medical college and hospital ,Chh.Sambhajinagar (aurangabad)dr

dr.shruti1204@gmail.com9975336706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026